Health & Research Goals
DSIP (Delta Sleep-Inducing Peptide)
DSIP (Péptido Inductor del Sueño Delta)
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated in the 1970s from rabbit brain tissue. Nam…
Primary Description
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated in the 1970s from rabbit brain tissue. Named for its ability to induce delta-wave (slow-wave) EEG activity, it is found endogenously in the hypothalamus, limbic system, pituitary, and various peripheral tissues. Unlike sedatives, DSIP does not force sleep but rather appears to facilitate the natural architecture of deep restorative sleep, potentially via GABA modulation, NMDA receptor interactions, and HPA axis normalization. The biohacker community uses it primarily as a sleep optimization and recovery tool.
Key Benefits
- Sleep quality
- Stress reduction
- Recovery
DSIP has a very short in vitro half-life of approximately 7–15 minutes due to aminopeptidase degradation. In vivo, it is thought to complex with carrier proteins that extend its effective duration. It is an amphiphilic peptide capable of crossing the blood-brain barrier — unusual and pharmacologically significant for a peptide of its size.
Demonstrated Effects
- Promotes delta-wave (slow-wave) sleep and deepens sleep architecture
- Reduces sleep latency and number of nighttime awakenings
- Normalizes disrupted sleep patterns including in chronic insomnia
- HPA axis modulation — reduces cortisol levels by an estimated 20–40% in some studies
- Adaptogenic stress-protective effects via neuroendocrine modulation
- Potential analgesic properties through endogenous opioid pathway enhancement
- Does not induce tolerance or dependence based on available research
- May influence GH secretion supporting nighttime recovery
Proposed Mechanisms of Action
1. GABAergic and NMDA Receptor Modulation
DSIP increases GABAergic inhibitory neurotransmission in cortical and limbic circuits while reducing excitatory glutamate signaling. It also decreases neuronal sensitivity to glutamate at NMDA receptors, reducing excitatory tone throughout the CNS.
Promotes the neurochemical environment conducive to delta-wave sleep onset and maintenance. Reduces the anxious, hyperactivated neural state that impairs sleep initiation and depth.
2. HPA Axis Normalization
DSIP attenuates corticotropin-releasing hormone (CRH) activity and normalizes cortisol diurnal rhythms. It is structurally homologous to glucocorticoid-induced leucine zipper (GILZ) and inhibits Raf-1 activation, suppressing ERK phosphorylation in the MAPK stress cascade.
Drives the cortisol-lowering, stress-buffering, and sleep-restorative effects. Particularly relevant for individuals with chronic stress-related sleep disruption or HPA axis dysregulation.
3. Blood-Brain Barrier Permeability
DSIP is amphiphilic and unusually able to cross the blood-brain barrier — a rare property for a peptide of its size. CSF concentrations correlate with plasma concentrations and peptide lipophilicity, enabling direct CNS activity after peripheral injection.
Allows subcutaneous injection to produce central nervous system effects. This is a key pharmacological advantage over many neuropeptides that cannot cross the BBB.
Research Evidence & Clinical Data
Investigated Applications
Sleep Optimization and Insomnia
Anecdotal: ModerateThe primary use in self-experimenting communities. Users report deeper, more restorative sleep and reduced time lying awake. Unlike traditional sedatives, DSIP is described as improving sleep quality rather than simply sedating. A notable feature: dosing during the day or early evening still improves that night's sleep and potentially several subsequent nights.
Preclinical basis: DSIP increases GABAergic inhibitory tone and reduces excitatory neurotransmission in cortical and limbic regions. It also interacts with NMDA receptors and the MAPK cascade. Early human trials (Schneider-Helmert 1988, Obál et al.) documented improved sleep architecture in chronic insomniacs.
Stress and Cortisol Management
Anecdotal: ModerateAthletes and high-stress individuals in the biohacker community use DSIP for its adaptogenic profile. It appears to normalize HPA axis dysregulation, which is a common issue in overtraining, chronic stress, and sleep deprivation. Users report feeling calmer, with reduced racing thoughts and improved emotional regulation.
Preclinical basis: DSIP attenuates CRH activity and normalizes diurnal cortisol rhythms. Homologous to glucocorticoid-induced leucine zipper (GILZ), it can inhibit Raf-1/ERK phosphorylation, interfering with the MAPK stress response cascade.
Recovery and Overtraining Syndrome
Anecdotal: EmergingAthletes dealing with overtraining syndrome — characterized by poor sleep, elevated resting cortisol, immune suppression, and impaired recovery — report DSIP helps restore normal sleep patterns and reduce the hyperactivated stress response associated with overtraining.
Preclinical basis: DSIP suppresses excess CNS free radical production, activates oxidative phosphorylation, and increases brain neuron hypoxia resistance — effects consistent with neuroprotection under physiological stress.
Pain Modulation
Anecdotal: LimitedLess commonly cited in community reports, but some users with chronic pain conditions report analgesic benefits. This aligns with research showing DSIP enhances enkephalin and endorphin signaling without opioid addiction risk.
Preclinical basis: DSIP enhances endogenous opioid signaling (enkephalins, endorphins) and demonstrates analgesic effects in animal models comparable to moderate doses of conventional analgesics.
Scientific References
- 1.
- 2.Delta-sleep-inducing peptide (DSIP): a reviewNeurosci Biobehav Rev1984
Safety Profile
Common Side Effects
- Morning grogginess or fatigue if dose is too high
- Headache or dizziness — uncommon
- Injection site reactions: mild redness or irritation
- Vivid dreams — reported by some users, generally not distressing
- Potential hormonal modulation (LH and GH may be affected) — data limited
- Individual variability: some users report no subjective effect at standard doses
- Minimal
- Morning grogginess (rare)
Contraindications
- Known hypersensitivity to DSIP
- Pregnancy and breastfeeding (insufficient safety data)
- Caution in individuals with seizure disorders (GABAergic modulation may affect seizure threshold — data limited)
- Concurrent use of sedative medications (additive CNS depression possible)
- None well-established
Pre-Use Screening Checklist
Benzodiazepines, Z-drugs, antihistamines, or other sedatives may have additive CNS effects with DSIP. Start with lower dose if using concurrently.
Rule out sleep apnea and other primary sleep disorders before attributing poor sleep to conditions potentially addressable by DSIP. Treating the wrong root cause delays effective intervention.
DSIP may influence LH and GH secretion. Baseline hormone panel useful for monitoring in those on hormonal therapies.
Legal & Regulatory Status
Not FDA approved. Research compound only. No approved indication in the United States.
Not specifically listed on WADA Prohibited List. However, any substance with demonstrated performance-enhancing effects could fall under catch-all clauses.
Not approved. Research compound.
Not approved by EMA. Research compound. In Russia, DSIP was developed into a pharmaceutical product called Deltaran.
Not TGA approved. Research compound.
Research Protocols
Dosing Protocols
Sleep optimization
SubcutaneousStress recovery and cortisol normalization
SubcutaneousRoutes of Administration
Subcutaneous injection
Most commonStandard subcutaneous injection into abdomen or thigh using insulin syringe. Most reliable bioavailability route.
Rotate injection sites. Very short in vitro half-life (minutes), but in vivo carrier protein binding extends functional duration.
Intranasal (nasal spray)
Less commonSome community members report using DSIP as an intranasal preparation given its BBB permeability. Less standardized than injection.
Absorption and bioavailability via intranasal route is not well-characterized. Not a standard community practice.
Reconstitution Guide
Bacteriostatic water (BAC water) preferred
Add BAC water slowly to lyophilized DSIP powder. Swirl gently to dissolve. Do not shake. DSIP powder can be particularly delicate — handle with care.
For a 5 mg vial: add 2.5 mL BAC water = 2 mg/mL (2000 mcg/mL). A 500 mcg dose = 0.25 mL drawn; a 1 mg dose = 0.5 mL drawn; a 2 mg dose = 1 mL drawn.
Refrigerate at 2–8°C. Use within 28 days. DSIP may be more susceptible to degradation than some peptides — minimize air exposure.
Store lyophilized at -20°C. Protect from heat and light. Shelf stable for 12–24 months when properly stored.
Key insight: DSIP does not need to be taken immediately before sleep. Daytime or early evening dosing (2–3 hours before intended sleep) is effective and may improve sleep quality for several subsequent nights. This reflects its mechanism — modulating neuroendocrine pathways rather than directly sedating.
Pharmacokinetics
| Half-Life | Approximately 7–15 minutes in vitro (plasma). In vivo functional duration is extended by carrier protein binding — the precise in vivo half-life is not well-characterized. Effects on sleep architecture can persist for multiple nights after a single dose, suggesting downstream neuroendocrine mechanisms that outlast plasma clearance. |
| Absorption | Subcutaneous absorption is the primary route used. DSIP is amphiphilic and crosses the blood-brain barrier, a critical property that enables CNS effects after peripheral injection. CSF concentrations correlate with plasma levels and peptide lipophilicity. |
| Distribution | Distributed throughout the brain (hypothalamus, limbic system, pituitary) and peripheral organs. Found in both free and protein-bound forms in vivo. Co-localizes with ACTH, MSH, TSH, and MCH in the pituitary. |
| Metabolism | Rapid degradation by aminopeptidase-like enzymes. Renal and hepatic clearance of breakdown products. Carrier protein complexation in vivo may significantly slow effective clearance. |
| Molecular Structure | Nine amino acid nonapeptide. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Molecular formula: C35H48N10O15. MW: 848.8 g/mol. Amphiphilic structure enabling BBB crossing. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Sleep quality (subjective or wearable)Track sleep depth, number of awakenings, and morning restedness. Most users notice effects within 1–7 days. Non-response by 2 weeks may indicate dose adjustment needed.Check: Daily during protocol
- Daytime fatigue and cognitive clarityExcessive morning grogginess suggests dose is too high or timing is too close to sleep. Adjust timing to 2–3 hours before bed.Check: Daily
Critical Warning Signs
- Excessive daytime sedation or inability to wake fullyReduce dose by 50% and increase time between injection and sleep. Rule out interaction with other sedatives.Urgency: Within 24-48 hours
- Unusual hormonal symptoms (unexpected menstrual changes, gynecomastia, etc.)Check LH and GH levels. Discontinue pending evaluation as DSIP has documented effects on pituitary hormone secretion.Urgency: Within 1 week if persistent
Featured in Stacking Protocols
Community-researched combinations involving this compound
BPC-157
BPC-157 Recovery StackRecovery and sleep optimization stack for overtraining or high-stress periods
DSIP addresses the neuroendocrine/sleep component of recovery; BPC-157 provides systemic anti-inflammatory and tissue repair effects. Together they address both the neural recovery (sleep architecture, HPA axis normalization) and physical recovery (tissue healing, GI health) dimensions.
DSIP 100–300 mcg sub-Q 2–3 hours before bed; BPC-157 250–500 mcg daily sub-Q. Cycle 4–6 weeks.
Epithalon
Longevity & Telomere StackLongevity-focused sleep and circadian restoration stack
Epithalon restores pineal gland function and melatonin production (particularly in older users), while DSIP directly improves delta-wave sleep architecture. Together they address circadian disruption at both the endocrine (melatonin, pineal) and neuroelectrophysiological (delta wave, GABA) levels.
DSIP 100–200 mcg sub-Q evenings; Epithalon 5 mg sub-Q for 10-day cycle. Run together or sequentially.
Selank
Cognitive & Anxiolytic StackAnxiety and stress stack for stress-driven sleep disruption
Selank (anxiolytic neuropeptide) reduces anxiety-driven sleep disruption and HPA hyperactivity during the day; DSIP addresses the sleep architecture component at night. Complementary without significant overlap in mechanisms.
Selank 250–500 mcg intranasal or sub-Q during the day; DSIP 100–200 mcg sub-Q 2–3 hours before bed.